In English | En español
Questions About Cancer? 1-800-4-CANCER

Clinical Trials Search Results

View Content for:
Display:
  •          
Help with display options.
Results 1-24 of 24 for your search:
Cancer Type/Condition:  Brain tumor, child: Other
Stage/Subtype:  childhood supratentorial ependymoma
Trial Type:  Treatment
Trial Status:  Active
Start Over
        Show
1.

Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 1 to 21
Sponsor: NCI, Other
Protocol IDs: ACNS0831, NCI-2011-02029, COG-ACNS0831, CDR0000668560, U10CA098543, NCT01096368
2.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 2 to 32
Sponsor: Pharmaceutical / Industry
Protocol IDs: CNS 0201, NCT00179907
3.

Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 1 to 21
Sponsor: NCI, Other
Protocol IDs: CDR0000647587, COG-ADVL0912, ADVL0912, NCT00939770
4.

Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 4 to 21
Sponsor: Other
Protocol IDs: 10-096, NCT01294670
5.

Phase: Phase II
Type: Treatment
Status: Active
Age: 3 to 20
Sponsor: Other
Protocol IDs: SIOP-EPENDYMOMA-99, AIEOP-EPENDYMOMA-99, CCLG-EPENDYMOMA-99, EU-99001, NCT00004224
6.

Phase: Phase II
Type: Treatment
Status: Active
Age: 21 and under
Sponsor: Other
Protocol IDs: CCLG-CNS-2001-4, EU-20576, NCT00278252
7.

Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Any age
Sponsor: Other
Protocol IDs: 05-122, MSKCC-05122, NCT00445965
8.

Phase: Phase II
Type: Treatment
Status: Active
Age: 6 months to 17 years
Sponsor: Other
Protocol IDs: CDR0000066490, BC-BT-10, NCT00003458
9.

Phase: Phase II
Type: Natural history/Epidemiology, Treatment
Status: Active
Age: 1 to 25
Sponsor: NCI, Other
Protocol IDs: 10-206, NCT01288235
10.

Phase: Phase II
Type: Treatment
Status: Active
Age: 21 and under
Sponsor: Other
Protocol IDs: SNUCH-SCT-1102, NCT01342237
11.

Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 3 to 18
Sponsor: Pharmaceutical / Industry
Protocol IDs: BO25041, 2010-022189-28, ITCC-019, HGG-01, NCT01390948
12.

Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 months to 21 years
Sponsor: NCI
Protocol IDs: NCI-2011-03536, ACNS1021, U10CA098543, COG-ACNS1021, NCT01462695
13.

Phase: Phase II
Type: Treatment
Status: Active
Age: 6 to 18
Sponsor: Other
Protocol IDs: HSJD-GLIOMAS-IC, NCT01574092
14.

Phase: Phase I
Type: Treatment
Status: Active
Age: 3 to 70
Sponsor: Other
Protocol IDs: MCW-7594, MCW-CHW-511, MCW-CHW-9411, NCI-V95-0652, NCT00002647
15.

Phase: Phase I
Type: Treatment
Status: Active
Age: 2 to 25
Sponsor: NCI, Other
Protocol IDs: CDR0000257582, UIHC-200008086, NCI-V02-1710, 200008086, NCT00049023
16.

Phase: Phase I
Type: Treatment
Status: Approved-not yet active
Age: 3 to 21
Sponsor: Other
Protocol IDs: CNS 1100, NCT00836628
17.

Phase: Phase I
Type: Treatment
Status: Active
Age: 3 to 22
Sponsor: Pharmaceutical / Industry
Protocol IDs: 07-098, NCT00634231
18.

Phase: Phase I
Type: Treatment
Status: Active
Age: 18 months to 23 years
Sponsor: Other
Protocol IDs: ACH-CNS-001, NCT00876993
19.

Phase: Phase I
Type: Treatment
Status: Active
Age: Under 18
Sponsor: NINDS
Protocol IDs: 090117, 09-N-0117, NCT00880061
20.

Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Under 19 at diagnosis
Sponsor: NCI
Protocol IDs: NCI-2011-02539, 10-C-0219, CDR0000687467, NCI-10-C-0219, 8449, NCT01226940
21.

Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 2 to 21
Sponsor: Other
Protocol IDs: SorIrin1576, NCT01518413
22.

Phase: No phase specified
Type: Treatment
Status: Active
Age: 0 to 21
Sponsor: Other
Protocol IDs: GPOH-HIT-2000, EU-205105, NCT00303810
23.

Phase: No phase specified
Type: Natural history/Epidemiology, Treatment
Status: Active
Age: 2 to 25
Sponsor: Other
Protocol IDs: 2005P001629, NCT01115777
24.

Phase: No phase specified
Type: Treatment
Status: Active
Age: 70 and under
Sponsor: Other
Protocol IDs: 2011OC057, MT2011-09C, NCT01505569
New Search